Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Corcept Therapeutics Inc (CORT)

416 + Investors. Track Smart Money conviction in CORT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +77
Streak
1Q ▲
Buyers last Q
62%

Smart Money Signals — CORT

Based on 427 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added CORT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
427 hedge funds hold CORT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
〰️

Stable — ownership unchanged year-over-year

fund count last 6Q
The number of hedge funds holding CORT is almost the same as a year ago (+7 funds, +2% change). No significant rush to buy or sell — institutional backing is holding steady.
🟢

More buyers than sellers — 62% buying

280 buying168 selling
Last quarter: 280 funds were net buyers (130 opened a brand new position + 150 added to an existing one). Only 168 were sellers (115 trimmed + 53 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+61 vs last Q)

new funds entering per quarter
Funds opening a new CORT position: 62 → 66 → 69 → 130. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 24% medium ■ 25% new
215 out of 427 hedge funds have held CORT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +117% but shares only +13% — price-driven

Value
+117%
Shares
+12%
Last quarter: the total dollar value of institutional holdings rose +117%, but actual share count only changed +13%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

68 → 62 → 66 → 69 → 130 new funds/Q
New funds entering each quarter: 62 → 66 → 69 → 130. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 58% veterans vs 25% newcomers

■ 58% veterans ■ 18% 1-2yr ■ 25% new
Entry-cohort mix of 445 holders: 256 (58%) are 2+ year veterans, 78 entered 1–2 years ago, and 111 (25%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 54% AUM from top-100 funds

54% from top-100 AUM funds
56 of 419 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in CORT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CORT

In 2026 Q2, 280 hedge funds were net buyers of CORT (130 opened a new position, 150 added to an existing one), while 168 reduced or exited (115 trimmed, 53 sold completely) — a 62% buyer ratio, indicating clear institutional accumulation. 54% of total institutional value in CORT is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +77 funds (more new holders than closures). Total institutional holders: 427.

Hedge Fund Ownership: CORT

How many hedge funds hold CORT — quarterly history vs. share price
Quarterly hedge fund ownership of CORT vs. share price

Market Analysis: CORT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CORT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Corcept Therapeutics Inc (CORT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CORT has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 80d ago
CORT
+28.6%
XLV
+6.4%

CORT outperformed XLV by +22.2% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 35d ago
CORT
-2.3%
XLV
+0.9%

Since the filing became public, CORT outperformed XLV by -3.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

18 top-rated funds 5 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: CORT
416 + Investors

Track Smart Money conviction in CORT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 416 350 18.86%
13F Shares 84M 83M 1.15%
Total Value $6.54B $3.06B 113.39%
New Positions 129 69 +60
Increased Positions 142 111 +31
Closed Positions 55 108 -53
Reduced Positions 113 128 -15
Total Calls 15 11 36.36%
Total Puts 10 7 42.86%
PUT/CALL Ratio 0.67 0.64 Bullish

Statistics: CORT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

416 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CORT. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CORT holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Propel Bio Management, LLC 6.21% 136,499 $11.9M
2 Tang Capital Management LLC 5.92% 1,500,000 $130.4M
3 Parallel Advisors, LLC 5.25% 3,962,177 $344.5M
4 MPM BioImpact LLC 4.09% 771,028 $67.0M
5 Birchview Capital, LP 2.33% 57,200 $5.0M
6 Diadema Partners LP 2.27% 206,300 $17.9M
7 Boxer Capital Management, LLC 2.20% 335,500 $29.2M
8 O'Neil Global Advisors, Inc. 1.91% 98,334 $8.6M
9 Lisanti Capital Growth, LLC 1.75% 91,610 $8.0M
10 Emerald Advisers, LLC 1.53% 748,325 $65.1M
11 FAS Wealth Partners, Inc. 1.47% 324,876 $28.2M
12 Brown Capital Management LLC 1.46% 84,041 $7.3M
13 S&T Bank/Pa 1.45% 55,553 $4.8M
14 Emerald Mutual Fund Advisers Trust 1.42% 464,902 $40.4M
15 Bridge City Capital, LLC 1.07% 53,823 $4.7M
16 Illumine Investment Management, LLC 1.03% — $1.6M
17 Granite Investment Partners, LLC 0.77% 172,228 $15.0M
18 Renaissance Technologies LLC 0.63% 5,261,628 $457.5M
19 Stanley-Laman Group, Ltd. 0.60% 68,196 $5.9M
20 Perceptive Advisors LLC 0.52% 398,385 $34.6M
21 Intellectus Partners, LLC 0.42% 28,000 $2.4M
22 F/m Investments LLC 0.39% 88,042 $7.7M
23 Yorktown Management & Research Co Inc 0.35% 6,500 $565K
24 Kennedy Capital Management LLC 0.31% 201,979 $17.6M
25 Rock Springs Capital Management LP 0.31% 72,000 $6.3M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Corcept Therapeutics Inc (CORT)

What does the Smart Money Trend signal show for CORT?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added CORT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CORT?

More buyers than sellers — 62% buying: Last quarter: 280 funds were net buyers (130 opened a brand new position + 150 added to an existing one). Only 168 were sellers (115 trimmed + 53 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CORT holders?

Elite ownership — 54% AUM from top-100 funds: 56 of 419 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in CORT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CORT?

50% of holders stayed for 2+ years: 215 out of 427 hedge funds have held CORT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Corcept Therapeutics Inc (CORT) following the 2026 Q2 hedge fund 13F filings?

As of today, CORT has moved -2.3% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.9% for the XLV sector ETF — an outperformance of -3.2%. Since the quarter end (June 30, 2026), CORT has gained +28.6% vs +6.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →